Amendments to the Specification:

Please amend the specification by replacing the paragraph sections under the heading "Related Applications" with the following new paragraph sections:

At page 2, lines 34-37 to page 3, lines 1-8:

R^3 is in the 2-, 3- or 4-position and is:
carboxy; (C_{1-6})alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C_{1-6})alkyl, hydroxy(C_{1-6})alkyl, aminocarbonyl(C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{1-6})alkylsulphonyl, trifluoromethylsulphonyl, (C_{1-6})alkenylsulphonyl, (C_{1-6})alkoxycarbonyl, (C_{1-6})alkylcarbonyl, (C_{2-6})alkenyloxycarbonyl or (C_{2-6})alkenylcarbonyl and optionally further substituted by (C_{1-6})alkyl, hydroxy(C_{1-6})alkyl, aminocarbonyl(C_{1-6})alkyl or (C_{2-6})alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R^{10}; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R^{10}; or 5-oxo-1,2,4-oxadiazol-3-yl; or
(C_{1-4})alkyl **optionally substituted** or ethenyl substituted with any of the substituents listed above for R^3 and up to 3 groups R^{12} independently selected from:

At page 4, lines 11-19:

A is NR^{11} or CR^6R^7 and B is NR^{11}, O, SO_2 or CR^8R^9 and wherein:
each of R^6, R^7, R^8 and R^9 is independently selected from: hydrogen; (C_{1-6})alkylthio; halo; trifluoromethyl; azido; (C_{1-6})alkyl; (C_{2-6})alkenyl; (C_{1-6})alkoxycarbonyl; (C_{1-6})alkylcarbonyl; (C_{2-6})alkenyloxycarbonyl; (C_{2-6})alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents **R^{12} as defined** in R^3; (C_{1-6})alkylsulphonyl; (C_{2-6})alkenylsulphonyl; or (C_{1-6})aminosulphonyl wherein the amino group is optionally substituted by (C_{1-6})alkyl or (C_{1-6})alkenyl;
or R^6 and R^8 together represent a bond and R^7 and R^9 are as above defined;
or R^6 and R^7 or R^8 and R^9 together represent oxo;

At page 6, lines 3-9:

Preferred examples of R^3 include hydrogen; optionally substituted aminocarbonyl; optionally substituted $(C_{~~1-6~~ 1-4})$alkyl; carboxy(C_{1-4})alkyl; optionally substituted aminocarbonyl(C_{1-4})alkyl; cyano(C_{1-4})alkyl; optionally substituted 2-oxo-oxazolidinyl and optionally substituted 2-oxo-oxazolidinyl$(C_{1-4}$alkyl). More preferred R^3 groups are hydrogen; $CONH_2$; 1-hydroxyalkyl e.g. CH_2OH, $CH(OH)CH_2CN$; CH_2CO_2H; CH_2CONH_2; 1,2-dihydroxyalkyl e.g. $CH(OH)CH_2OH$; CH_2CN; 2-oxo-oxazolidin-5-yl and 2-oxo-oxazolidin-5-yl$(C_{1-4}$alkyl).

At page 8, lines 32-36 to page 9, lines 1-31:

In a further aspect of the invention there is provided a process for preparing compounds of formula (I), and pharmaceutically acceptable derivatives thereof, which process comprises:

reacting a compound of formula (IV) with a compound of formula (V):



(IV)



(V)

wherein Z^1, Z^2, Z^3, Z^4, Z^5 and n are as defined in formula (I); $R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ are R^1, R^2, R^3 and R^4 as defined in formula (I) or groups convertible thereto;

and X and Y may be the following combinations:

(i) X is A'-COW, Y is H and n is 0;

(ii) X is $CR^6=CR^8R^9$, Y is H and n is 0;

(iii) X is oxirane, Y is H and n is 0;

(iv) X is N=C=O and Y is H;

(v) X is NH_2 and Y is CO_2W;

(vi) one of X and Y is CO_2R^y and the other is $CH_2CO_2R^x$;

(vii) X is CHR^6R^7 and Y is CR^8O;

(viii) X is $CR^6=PR^z_3$ and Y is CR^8O;

(ix) X is CR^6O and Y is $CR^8=PR^z_3$;

(x) one of X and Y is COW and the other is $NHR^{11'}$ ~~or NCO~~;

(xi) X is CR^6O and Y is $NHR^{11'}$ or X is $NHR^{11'}$ and Y is C R^8O;

(xii) X is $NHR^{11'}$ and Y is CR^8R^9W;

(xiii) X is CR^6R^7W and Y is $NR^{11'}$ or O; or

(xiv) X is $CR^6R^7SO_2W$ and Y is H and n=0;

(xv) X is $NR^{11'}$ and Yis SO_2W;

in which W is a leaving group, e.g. halogen; R^x and R^y are (C_{1-6})alkyl; R^z is aryl or (C_{1-6})alkyl; A' and $NR^{11'}$ are A and NR^{11} as defined in formula (I), or groups convertible thereto; and oxirane is:



wherein R^6, R^8 and R^9 are as defined in formula (I);

and thereafter optionally or as necessary converting A', $R^{1'}$, $R^{2'}$, $R^{3'}$, $R^{4'}$ and $NR^{11'}$;to A, R^1, R^2, R^3, R^4 and $NR^{11'}$; converting A-B to other A-B, interconverting R^1, R^2, R^3 and/or R^4, and/or forming a pharmaceutically acceptable derivative thereof.